Vaccine Safety

@article{Su2019VaccineS,
  title={Vaccine Safety},
  author={John R Su and Jonathan Duffy and Tom T. Shimabukuro},
  journal={Vaccinations},
  year={2019}
}

References

SHOWING 1-10 OF 128 REFERENCES
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
TLDR
The Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
TLDR
AS01 adjuvantation shows good prospects for use in new vaccines targeted to populations with challenging immune statuses and against diseases caused by complex pathogens, and depends on synergistic activities of QS-21 and MPL.
Approach to skin and soft tissue infections in non-HIV immunocompromised hosts
TLDR
The changing epidemiology and clinical manifestations of the most common cutaneous pathogens in non-HIV immunocompromised hosts, including patients with solid organ transplants, stem cell transplant, solid tumors, hematologic malignancies, and receiving chronic immunosuppressive therapy for inflammatory disorders are reviewed.
Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses
TLDR
Future studies of ASD risk factors would benefit from a developmental psychopathology approach, prospective design, precise exposure measurement, reliable timing of exposure in relation to critical developmental periods and should take into account the dynamic interplay between gene and environment by using genetically informed designs.
Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats
TLDR
There was no evidence that intramuscular administration of the test articles promoted inflammation or damage in the CNS, or blood-brain barrier disruption, in this model and CNS analyses revealed neither microglia activation nor inflammatory cellular infiltrates in the brain.
Guillain‐Barré Syndrome
Manufacture of Oil-in-Water Emulsion Adjuvants.
  • J. Haensler
  • Materials Science
    Methods in molecular biology
  • 2017
TLDR
Two manufacturing processes, high pressure homogenization (HPH or microfluidization) and a phase inversion temperature method (PIT), are described to yield fine and long-term stable emulsion adjuvants for human vaccines.
Overview of Vaccine Adjuvants: Introduction, History, and Current Status.
TLDR
The goal in this chapter is to define the concept, need, and mechanism of adjuvants in the vaccine field while describing its history, present use, and future prospects.
...
1
2
3
4
5
...